Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion
- 1 May 1989
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (5) , 797-803
- https://doi.org/10.1016/0277-5379(89)90123-5
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- PHASE-I STUDY OF ECHINOMYCIN ADMINISTERED ON AN INTERMITTENT BOLUS SCHEDULE1985
- Echinomycin: The first bifunctional intercalating agent in clinical trialsInvestigational New Drugs, 1985
- Echinomycin Binding Sites on DNAScience, 1984
- Cytotoxic Activity of Echinomycin in a Human Tumor Cloning SystemCancer Drug Delivery, 1984
- Activity of two phase I drugs N-methylformamide (NSC-3051) and Echinomycin (NSC-526417) against fresh surgical explants of human tumors in the 6-day subrenal capsule (SRC) assayInvestigational New Drugs, 1983
- Clinical trials in cancer chemotherapyCancer, 1977
- The binding of echinomycin to deoxyribonucleic acidBiochemical Journal, 1976
- Structure revision of the antibiotic echinomycinJournal of the American Chemical Society, 1975
- Structure of quinomycin antibiotics.The Journal of Antibiotics, 1975
- Stoffwechselprodukte von Actinomyceten. 7. Mitteilung. EchinomycinHelvetica Chimica Acta, 1957